ChromaForge Research Platform
Rewrite the code of life at unprecedented speed.
Overview
ChromaForge represents Unzyme Laboratories' most ambitious contribution to the gene editing field: a comprehensive research acceleration platform that integrates three breakthrough CRISPR technologies into a single unified workflow. Traditional CRISPR research is constrained by single-mutation targeting, off-target effects, and the inherent risks of double-strand DNA breaks. ChromaForge eliminates these limitations through our proprietary TriMode editing architecture, enabling researchers to accomplish in weeks what previously required years. The platform combines retron-based multi-locus editing, epigenetic modification without DNA cutting, and our enhanced vPE (Variant Prime Editor) system with 60x improved accuracy. Whether correcting complex polygenic disorders, activating silenced tumor suppressors, or engineering next-generation therapeutics, ChromaForge provides the precision and throughput modern gene therapy demands.
Key Features
RetroStack Multi-Locus Engine
Based on bacterial retron defense systems, RetroStack replaces entire DNA regions rather than targeting individual mutations. Correct dozens of variants in a single editing pass with 30%+ efficiency—previously unachievable in mammalian systems.
EpiSilence Module
Edit gene expression without touching the DNA sequence. Our methyl-stripping enzymes reactivate silenced genes by removing epigenetic markers, eliminating the cancer risks associated with double-strand breaks entirely.
vPE Precision Core
Engineered prime editors achieve error rates of 1:543—60 times more accurate than standard CRISPR-Cas9. Single-strand nicking with RNA-guided insertion ensures surgical precision at the nucleotide level.
Unified Bioinformatics Suite
AI-powered target selection, off-target prediction, and automated guide RNA design. The platform learns from every edit across our global research network, continuously improving accuracy.
Accelerating the Future of Gene Therapy
The path from CRISPR discovery to clinical application has historically spanned decades. ChromaForge compresses this timeline dramatically by addressing the three fundamental bottlenecks in gene editing research: precision, throughput, and safety.
Our platform emerged from Project PROMETHEUS, an internal initiative to develop gene therapies for conditions affecting Unzyme personnel and their families. When traditional methods proved inadequate, we engineered something better.
The TriMode Architecture
ChromaForge’s power lies in its integration of three complementary editing technologies:
RetroStack draws on bacterial retron systems—ancient defense mechanisms that bacteria use against viral infections. We’ve adapted these systems to perform large-scale DNA replacement in mammalian cells, achieving efficiency rates that make polygenic disease correction economically viable for the first time.
EpiSilence represents a philosophical shift in gene therapy. Rather than cutting DNA—with all the associated risks of chromosomal rearrangement and oncogenesis—we modify the chemical markers that control gene expression. Silenced genes awaken. Overactive genes quiet. The underlying code remains intact.
vPE Precision Core refines prime editing to its theoretical limits. By engineering novel Cas9 variants and stabilizing RNA templates with proprietary binding proteins, we’ve achieved accuracy levels that satisfy even the most conservative regulatory frameworks.
Research Applications
ChromaForge is currently deployed across 34 research institutions worldwide, with active programs in:
- Cystic fibrosis — RetroStack correction of CFTR variants (1,000+ mutations addressable with single platform)
- Sickle cell disease — EpiSilence reactivation of fetal hemoglobin genes
- Familial hypercholesterolemia — vPE correction of LDLR mutations
- Huntington’s disease — Epigenetic silencing of mutant HTT alleles
- Immuno-oncology — Multi-locus CAR-T engineering with enhanced persistence
Access Requirements
ChromaForge availability is restricted to qualified research institutions meeting our biosafety and competency standards. All users must complete Unzyme Laboratory Certification (UL-CERT) prior to platform access.
Prospective users undergo a comprehensive evaluation including:
- Institutional biosafety committee review
- Researcher credential verification
- Project ethical assessment
- Facility inspection (remote or on-site)
- Data sharing agreement execution
Approved institutions join the ChromaForge Research Network, gaining access to anonymized editing data from all network participants—a continuously growing dataset that improves prediction accuracy for all users.
Support and Training
Platform licensing includes:
- 40 hours of on-site installation and training
- Dedicated application scientist support (first 12 months)
- Access to ChromaForge Academy online curriculum
- Quarterly protocol updates and optimization recommendations
- Priority access to beta features and new editing modalities
The future of medicine is written in genetic code. ChromaForge provides the pen.
Contraindications
- Facilities without BSL-2 or higher certification
- Researchers lacking demonstrated CRISPR competency (UL-CERT required)
- Institutions in non-signatory countries to the Helsinki Biosafety Protocol
- Projects targeting human germline modification (unless pre-approved by Unzyme Ethics Board)
- Organizations with active litigation against Unzyme Laboratories or subsidiaries